Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. [electronic resource]
Producer: 20080930Description: 5116-23 p. digitalISSN:- 1078-0432
- Adenocarcinoma -- drug therapy
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis -- drug effects
- Bevacizumab
- Blotting, Western
- Boronic Acids -- administration & dosage
- Bortezomib
- Cell Line, Tumor
- Cetuximab
- Deoxycytidine -- administration & dosage
- ErbB Receptors -- drug effects
- Erlotinib Hydrochloride
- Female
- Humans
- Lactones -- administration & dosage
- Mice
- Mice, Nude
- Pancreatic Neoplasms -- drug therapy
- Phosphatidylinositol 3-Kinases -- drug effects
- Protease Inhibitors -- therapeutic use
- Proteasome Inhibitors
- Pyrazines -- administration & dosage
- Pyrroles -- administration & dosage
- Quinazolines -- administration & dosage
- Signal Transduction -- drug effects
- Xenograft Model Antitumor Assays
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.